About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 28 results
Filters: Keyword is Treatment Outcome  [Clear All Filters]
2022
A. Dispenzieri, Krishnan, A., Arendt, B., Blackwell, B., Wallace, P. K., Dasari, S., Vogl, D. T., Efebera, Y., Fei, M., Geller, N., Giralt, S., Hahn, T., Howard, A., Kohlhagen, M., Landau, H., Hari, P., Pasquini, M. C., Qazilbash, M. H., McCarthy, P., Shah, N., Vesole, D. H., Stadtmauer, E., and Murray, D., “Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).”, Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
2021
R. Nakamura, Saber, W., Martens, M. J., Ramirez, A., Scott, B., Oran, B., Leifer, E., Tamari, R., Mishra, A., Maziarz, R. T., McGuirk, J., Westervelt, P., Vasu, S., Patnaik, M., Kamble, R., Forman, S. J., Sekeres, M. A., Appelbaum, F., Mendizabal, A., Logan, B., Horowitz, M., and Cutler, C., “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
E. J. Fuchs, O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., Devine, S., Horowitz, M. M., Horwitz, M. E., Karanes, C., Leifer, E., Magenau, J. M., McGuirk, J. P., Morris, L. E., Rezvani, A. R., Jones, R. J., and Brunstein, C. G., “Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.”, Blood, vol. 137, no. 3, pp. 420-428, 2021.
2020
M. J. Martens and Logan, B. R., “Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.”, Lifetime Data Anal, vol. 26, no. 3, pp. 603-623, 2020.
2019
M. J. Levis, Bin Chen, Y. -, Hamadani, M., Horowitz, M. M., and Jones, R. J., “FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?”, J Clin Oncol, vol. 37, no. 19, pp. 1604-1607, 2019.
A. A. King, McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., Kamani, N., and Shenoy, S., “Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.”, Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
2018
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
M. J. Martens and Logan, B. R., “A group sequential test for treatment effect based on the Fine-Gray model.”, Biometrics, vol. 74, no. 3, pp. 1006-1013, 2018.
C. E. Allen, Marsh, R., Dawson, P., Bollard, C. M., Shenoy, S., Roehrs, P., Hanna, R., Burroughs, L., Kean, L., Talano, J. - A., Schultz, K. R., Pai, S. - Y., K Baker, S., Andolina, J. R., Stenger, E. O., Connelly, J., Ramirez, A., Bryant, C., Eapen, M., and Pulsipher, M. A., “Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.”, Blood, vol. 132, no. 13, pp. 1438-1451, 2018.
2017
A. D'Souza, Pasquini, M., Logan, B., Giralt, S., Krishnan, A., Antin, J., Howard, A., Goodman, S., Qazilbash, M., Knust, K., Sahebi, F., Weisdorf, D., Vesole, D., Stadtmauer, E., Maloney, D., and Hari, P., “Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.”, Br J Haematol, vol. 178, no. 5, pp. 816-819, 2017.
M. Eapen, Kurtzberg, J., Zhang, M. - J., Hattersely, G., Fei, M., Mendizabal, A., Chan, K. Wah, De Oliveira, S., Schultz, K. R., Wall, D., Horowitz, M. M., and Wagner, J. E., “Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
2016
J. C. Alvarnas, Le Rademacher, J., Wang, Y., Little, R. F., Akpek, G., Ayala, E., Devine, S., Baiocchi, R., Lozanski, G., Kaplan, L., Noy, A., Popat, U., Hsu, J., Morris, L. E., Thompson, J., Horowitz, M. M., Mendizabal, A., Levine, A., Krishnan, A., Forman, S. J., Navarro, W. H., and Ambinder, R., “Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.”, Blood, vol. 128, no. 8, pp. 1050-8, 2016.
B. E. Shaw, Lee, S. J., Horowitz, M. M., Wood, W. A., Rizzo, J. D., and Flynn, K. E., “Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN.”, Bone Marrow Transplant, vol. 51, no. 9, pp. 1173-9, 2016.
P. V. O'Donnell, Eapen, M., Horowitz, M. M., Logan, B. R., DiGilio, A., Brunstein, C., Fuchs, E. J., Flowers, M. E. D., Salit, R., Raj, K., Pagliuca, A., Bradstock, K., Granata, A., Castagna, L., Furst, S., and Blaise, D., “Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.”, Bone Marrow Transplant, vol. 51, no. 12, pp. 1599-1601, 2016.
J. M. Knight, Syrjala, K. L., Majhail, N. S., Martens, M., Le-Rademacher, J., Logan, B. R., Lee, S. J., Jacobsen, P. B., Wood, W. A., Jim, H. S. L., Wingard, J. R., Horowitz, M. M., Abidi, M. H., Fei, M., Rawls, L., and J Rizzo, D., “Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.”, Biol Blood Marrow Transplant, vol. 22, no. 12, pp. 2256-2263, 2016.
W. A. Wood, Le-Rademacher, J., Syrjala, K. L., Jim, H., Jacobsen, P. B., Knight, J. M., Abidi, M. H., Wingard, J. R., Majhail, N. S., Geller, N. L., J Rizzo, D., Fei, M., Wu, J., Horowitz, M. M., and Lee, S. J., “Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).”, Cancer, vol. 122, no. 1, pp. 91-8, 2016.
G. G. Laport, Wu, J., Logan, B., Bachanova, V., Hosing, C., Fenske, T., Longo, W., Devine, S. M., Nademanee, A., Gersten, I., Horowitz, M., Lazarus, H. M., and Riches, M. L., “Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ”, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
2015
S. G. Holtan, Verneris, M. R., Schultz, K. R., Newell, L. F., Meyers, G., He, F., DeFor, T. E., Vercellotti, G. M., Slungaard, A., MacMillan, M. L., Cooley, S. A., Blazar, B. R., Panoskaltsis-Mortari, A., and Weisdorf, D. J., “Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.”, Biol Blood Marrow Transplant, vol. 21, no. 6, pp. 1029-36, 2015.
N. Khera, Majhail, N. S., Brazauskas, R., Wang, Z., He, N., Aljurf, M. D., Akpek, G., Atsuta, Y., Beattie, S., Bredeson, C. N., Burns, L. J., Dalal, J. D., Freytes, C. O., Gupta, V., Inamoto, Y., Lazarus, H. M., LeMaistre, C. F., Steinberg, A., Szwajcer, D., Wingard, J. R., Wirk, B., Wood, W. A., Joffe, S., Hahn, T. E., Loberiza, F. R., Anasetti, C., Horowitz, M. M., and Lee, S. J., “Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.”, Biol Blood Marrow Transplant, vol. 21, no. 10, pp. 1815-22, 2015.
S. M. Devine, Owzar, K., Blum, W., Mulkey, F., Stone, R. M., Hsu, J. W., Champlin, R. E., Bin Chen, Y. -, Vij, R., Slack, J., Soiffer, R. J., Larson, R. A., Shea, T. C., Hars, V., Sibley, A. B., Giralt, S., Carter, S., Horowitz, M. M., Linker, C., and Alyea, E. P., “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo”, J Clin Oncol, vol. 33, no. 35, pp. 4167-75, 2015.
2014
J. L. M. Ferrara, “Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.”, Biol Blood Marrow Transplant, vol. 20, no. 2, pp. 149-53, 2014.
G. A. Yanik, Horowitz, M. M., Weisdorf, D. J., Logan, B. R., Ho, V. T., Soiffer, R. J., Carter, S. L., Wu, J., Wingard, J. R., DiFronzo, N. L., Ferrara, J. L., Giralt, S., Madtes, D. K., Drexler, R., White, E. S., and Cooke, K. R., “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
2012
M. C. Pasquini, Devine, S., Mendizabal, A., Baden, L. R., Wingard, J. R., Lazarus, H. M., Appelbaum, F. R., Keever-Taylor, C. A., Horowitz, M. M., Carter, S., O'Reilly, R. J., and Soiffer, R. J., “Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl”, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
2011
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
S. M. Devine, Carter, S., Soiffer, R. J., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Stadtmauer, E. A., Alyea, E. P., Keever-Taylor, C. A., and O'Reilly, R. J., “Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot”, Biol Blood Marrow Transplant, vol. 17, no. 9, pp. 1343-51, 2011.